Apexigen

Apexigen is a clinical-stage biopharmaceutical company founded in 2010 with a focus on creating transformative immunotherapies for patients with cancer. The company is dedicated to discovering and developing a new generation of antibody therapeutics for the treatment of cancer, particularly emphasizing new immuno-oncology products designed to harness the patient’s immune system to combat and eradicate cancer. Its lead immuno-oncology drug candidate, sotigalimab, is a potent immune-activating antibody against CD40 that is currently in Phase 2 clinical development.

Apexigen operates within the biopharma, biotechnology, health care, and pharmaceutical industries, with its headquarters based in the United States. In its most recent fundraising activity, the company secured a $2.80 million Post-IPO Equity investment on 24 January 2023.

Apexigen's commitment to pioneering immunotherapies for cancer patients and its notable progress in clinical development make it a compelling venture for potential investors seeking opportunities in the biopharmaceutical sector.